spacer
home > pmps > summer 2002 > liposomes - successful carrier systems for targeted drug delivery
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Liposomes - Successful Carrier Systems for Targeted Drug Delivery

Liposomes are colloidal, vesicular structures based on (phospho) lipid bilayers. Their characteristics depend on the manufacturing protocol and choice of bilayer components. They can be as small as 20nm and as large as 10Mm in diameter. The liposomes can be unilamellar (meaning only one bilayer surrounds an aqueous core) or multilamellar (several bilayers concentrically oriented around an aqueous core). Moreover, the choice of bilayer components determines the rigidity (or fluidity) and the charge of the bilayer. For example, saturated phospholipids with long acyl chains such as dipalmitoylphosphatidylcholine, form a rigid, rather impermeable bilayer structure, while the unsaturated phosphatidylcholine species from natural sources (egg or soy bean phosphatidylcholine) give much more permeable and less stable bilayers. The introduction of positively or negatively charged lipids provides the liposomes a surface charge. Liposome surfaces can be readily modified. By attaching polyethylene glycol (PEG) units to the bilayer, the circulation time of liposomes in the bloodstream is dramatically increased. Alternatively, homing molecules can be attached to liposome bilayers to make these structures target site specific. Size, lamellarity, bilayer rigidity, charge and bilayer surface modifications all determine the fate of liposomes on the shelf and in vivo. Over the years the behaviour of liposomes has been investigated in much detail (1,2) and algorithms can be used to help the pharmaceutical formulation scientist in selecting the proper liposome type.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daan Crommelin and Gert Bos of OctoPlus and Gert Storm of the Utrecht Institute for Pharmaceutical Sciences, The Netherlands Professor Daan Crommelin PhD is a Professor at the Department of Pharmaceutics at Utrecht University. He is Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS) and Adjunct Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah.
His research focuses on advanced drug delivery and drug targeting strategies. He has published over 240 articles in peer-reviewed journals. Daan is also Chief Scientific Officer of OctoPlus, a Leiden-based company specialising in the development of pharmaceutical product formulations and advanced drug delivery systems..

Gert Bos PhD obtained his masters degree in Chemical Technology in 1993 at the University of Twente. He subsequently earned his PhD in the field of Biomaterial Science from the same university.
He currently combines a postdoctoral research and development function at the faculty of Pharmaceutical Sciences of the Utrecht University (UIPS) and a business development position at OctoPlus in the Netherlands.

Professor Gert Storm PhD obtained is PhD in 1987 on a thesis entitled, Liposomes as delivery system for doxorubicin in cancer therapy. He was appointed as Professor (Drug Targeting Chair) at the University of Utrecht in 2000, and in 1999 as Adjunct Professor at the department of pharmaceutics at the Royal School of Pharmacy, Copenhagen, Denmark. His research interests are in the field of biopharmaceutics and drug targeting.
He published over 180 original articles, reviews and book chapters. He is a member of the editorial (advisory) board of the J. Drug Targeting, J. Liposome Research, S.T.P. Pharma Sciences and Eur. J. Pharm. Sciences, and is Special Features Editor of Pharm. Research. He acts as a Consultant to a number of pharmaceutical companies.

spacer
Gert Bos
spacer
spacer
spacer
Daan Crommelin
spacer
spacer
spacer
Gert Storm
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement